Forwarded from 📡Guardians of Hong Kong
Brazil Halts the Final Stage China Vaccine Trial, Claims Serious Adverse Reaction
The Brazilian National Health Surveillance Agency on Monday announced that it has suspended the clinical trials of China's Sinovac COVID-19 vaccines, citing "serious adverse reactions" that occurred during the testing last month (29 October), But the authority did not provide further details, nor explained why it took more than a week to announce the problem.
Sinovac Biotech has been cooperating with Butantan, an institute at the State of Sao Paulo, to develop COVID-19 vaccines, called CoronaVac. The institute was surprised by ANVISA's decision, said it said was investigating the incident and will held a press conference on Tuesday morning local time.
#China #Brazil #SaoPaulo #SinovacBiotech #Butantan #CoronaVac #ANVISA #COVID19 #WuhanVirus #Vaccine
Source: Stand News #Nov10
https://bit.ly/2H6uwYI
The Brazilian National Health Surveillance Agency on Monday announced that it has suspended the clinical trials of China's Sinovac COVID-19 vaccines, citing "serious adverse reactions" that occurred during the testing last month (29 October), But the authority did not provide further details, nor explained why it took more than a week to announce the problem.
Sinovac Biotech has been cooperating with Butantan, an institute at the State of Sao Paulo, to develop COVID-19 vaccines, called CoronaVac. The institute was surprised by ANVISA's decision, said it said was investigating the incident and will held a press conference on Tuesday morning local time.
#China #Brazil #SaoPaulo #SinovacBiotech #Butantan #CoronaVac #ANVISA #COVID19 #WuhanVirus #Vaccine
Source: Stand News #Nov10
https://bit.ly/2H6uwYI
Forwarded from 📡Guardians of Hong Kong
Indonesian Pharmaceutical Factory Changed Their Mind on the Uncertain Data after Saying 97% Validity for Chinese Vaccination
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
Forwarded from 📡Guardians of Hong Kong
Chinese COVID vaccine with unknown effectiveness? Don't worry, Hongkongers are the guinea pigs, despite the reverse response on a Brazilian testee, and the corruption between the manufacturer and officials.
#COVID19 #ChineseVaccine #SinoVacBiotech #GoHKGraphics
#COVID19 #ChineseVaccine #SinoVacBiotech #GoHKGraphics
Forwarded from 📡Guardians of Hong Kong
Brazilian Health Authorities Criticise the Low Transparency of the Chinese Vaccine Emergency Use Standard
Whether using vaccine manufactured by the Chinese company Sinovac Biotech caused controversy in Brazil again and involved in Brazilian partisan debate.
ANVISA, a Brazilian Health Regulatory Agency, expressed their concerns over the COVID-19 vaccines on Monday as the Chinese public health departments approved the vaccine for emergency use without adequate transparency of the policy standards.
Jair Bolsonaro, the President of Brazil, has always criticised the Chinese vaccine that the “origin” of vaccine is not trustworthy. However, his political opponent, Sao Paulo Governor João Doria, who is regarded as the most capable of challenging the presidency in the 2022 presidential election, his state's research institute, is currently developing the vaccine CoronaVac with Sinovac. Doria even mentioned that they expect to distribute the vaccines to the local residents in January 2021.
#Vaccine #COVID19 #CovidVaccine #JoãoDoria #JairBolsonaro #SinovacBiotech #Brazil #ANVISA
Source: Stand News #Dec15
https://bit.ly/3ucWGEW
Whether using vaccine manufactured by the Chinese company Sinovac Biotech caused controversy in Brazil again and involved in Brazilian partisan debate.
ANVISA, a Brazilian Health Regulatory Agency, expressed their concerns over the COVID-19 vaccines on Monday as the Chinese public health departments approved the vaccine for emergency use without adequate transparency of the policy standards.
Jair Bolsonaro, the President of Brazil, has always criticised the Chinese vaccine that the “origin” of vaccine is not trustworthy. However, his political opponent, Sao Paulo Governor João Doria, who is regarded as the most capable of challenging the presidency in the 2022 presidential election, his state's research institute, is currently developing the vaccine CoronaVac with Sinovac. Doria even mentioned that they expect to distribute the vaccines to the local residents in January 2021.
#Vaccine #COVID19 #CovidVaccine #JoãoDoria #JairBolsonaro #SinovacBiotech #Brazil #ANVISA
Source: Stand News #Dec15
https://bit.ly/3ucWGEW
Forwarded from 📡Guardians of Hong Kong
Brazil Stops Purchasing more Coronavac Vaccine and Does not Recommend for the 3rd Dose Booster
Brazil is a major customer of China's Coronavac. However, due to the rising efficacy concerns against the COVID Delta variant, along with other vaccines becoming more accessible, the Brazilian government pauses the Coronavac vaccines purchases and encourages people not to use it for a third booster shot. The CoronaVac vaccine factory originally planned to be built in Brazil is also unknown whether it will be built as scheduled.
The Wall Street Journal mentions that Brazil has almost fully purchased 100 million doses of China’s CoronaVac shot. However, the Brazilian government no longer recommends using CoronaVac as a booster dose, but Pfizer instead due to the low protective rates of CoronaVac.
According to the Brazilian government data, the Chinese shot accounted for 80% of the doses at the beginning of the year due to the National Immunization Programme but now declines to less than 35%. The data also shows two-thirds of Brazilians have had one vaccine shot, and just over a third have had two doses.
Source: Stand News #Sep13
https://bit.ly/39t1w7W
#COVID19 #SinovacBiotech #Coronavac #Pfizer #Brazil #WallStreetJournal #Vaccine #Booster
Brazil is a major customer of China's Coronavac. However, due to the rising efficacy concerns against the COVID Delta variant, along with other vaccines becoming more accessible, the Brazilian government pauses the Coronavac vaccines purchases and encourages people not to use it for a third booster shot. The CoronaVac vaccine factory originally planned to be built in Brazil is also unknown whether it will be built as scheduled.
The Wall Street Journal mentions that Brazil has almost fully purchased 100 million doses of China’s CoronaVac shot. However, the Brazilian government no longer recommends using CoronaVac as a booster dose, but Pfizer instead due to the low protective rates of CoronaVac.
According to the Brazilian government data, the Chinese shot accounted for 80% of the doses at the beginning of the year due to the National Immunization Programme but now declines to less than 35%. The data also shows two-thirds of Brazilians have had one vaccine shot, and just over a third have had two doses.
Source: Stand News #Sep13
https://bit.ly/39t1w7W
#COVID19 #SinovacBiotech #Coronavac #Pfizer #Brazil #WallStreetJournal #Vaccine #Booster